Figure 3.

Rationale for choosing an immunotherapy or a targeted therapy in second line or over: (a) immunotherapy; (b) targeted therapy.

Oncologists reported their reasons for prescribing an immunotherapy (a) or a targeted therapy (b) to their advanced BRAF-mutant melanoma patients in second line or over. Results are shown as the percentage of oncologists reporting a given reason for prescribing an immunotherapy or a targeted therapy. The percentages of oncologists are shown within the bars. Totals can sum to over 100% as specialists were allowed to report more than one reason to prescribe an immunotherapy or a targeted therapy. (a) Based on a total of 83 oncologists, of which 29 from academic centers, 14 community-based centers, and 40 private clinics. (b) Based on a total of 63 oncologists, of which 24 from academic centers, 12 community-based centers, and 27 private clinics.